



**BlueCross
BlueShield**

VYEPTI

Federal Employee Program. **PRIOR APPROVAL REQUEST**

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Send completed form to:
Service Benefit Plan
Prior Approval
P.O. Box 52080 MC 139
Phoenix, AZ 85072-2080
Attn. Clinical Services
Fax: **1-877-378-4727**

Patient Information (required)				Provider Information (required)		
Date:				Provider Name:		
Patient Name:				Specialty:		NPI:
Date of Birth:	Sex: <input type="checkbox"/> Male <input type="checkbox"/> Female			Office Phone:		Office Fax:
Street Address:				Office Street Address:		
City:	State:	Zip:		City:	State:	Zip:
Patient ID:	<div style="border: 1px solid black; padding: 2px;"> R </div>			Physician Signature:		
PHYSICIAN COMPLETES						

Vyepti

(eptinezumab-jjmr)

****Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit**

NOTE: Form must be completed in its **entirety for processing**

Is this request for brand or generic? ☐ Brand ☐ Generic

1. Will the patient need more than 3 vials every 90 days? ☐ Yes* ☐ No

***If YES**, please specify the requested quantity: _____ vials every 90 days

2. Is this medication being used for the prevention of migraines? ☐ Yes ☐ No

3. Will the patient require TWO calcitonin gene-related peptide (CGRP) antagonist medications for migraine therapy?

Please select answer below:

☐ **YES**, Vyepti is for PREVENTATIVE treatment and will be used with another CGRP for ACUTE treatment of migraines (Nurtec, Ubrelvy, Zavzpret). Acute and preventative CGRP combination therapy is covered if the patient is treatment resistant. **Please answer the below question:**

a. Has the patient completed an adequate 3-month trial of at least **TWO** of the following preventative CGRP antagonists: Aimovig, Ajovy, Emgality, Nurtec ODT, Qulipta, and/or Vyepti? ☐ Yes ☐ No*

***If NO**, has the patient completed an adequate 3-month trial of a triptan agent in combination with **ONE** of the preventative CGRP antagonists? ☐ Yes ☐ No

☐ **YES**, Vyepti is for PREVENTATIVE treatment and will be used with another CGRP for PREVENTATIVE treatment of migraines (Aimovig, Emgality, Ajovy, Qulipta, Nurtec).

☐ **NO**, Vyepti is for PREVENTATIVE treatment and the patient will be stopping the current CGRP therapy.

☐ **NO**, Vyepti is the **ONLY** CGRP the patient will be using.

5. Has the patient been on this medication continuously for the last **4 months** excluding samples? **Please select answer below:**

☐ **NO** – this is **INITIATION** of therapy, please answer the following question:

a. Has the patient taken a preventative CGRP medication in the past or is the patient switching from another preventative CGRP medication? ☐ Yes ☐ No*

***If NO**, does the patient have an intolerance or contraindication or have they had an inadequate treatment response to at least **TWO** of the following prophylactic agents: divalproex sodium/valproate sodium (Depakote/Depakote ER), topiramate (Topamax), amitriptyline (Elavil), nortriptyline (Pamelor), venlafaxine (Effexor), duloxetine (Cymbalta), or a beta-blocker such as atenolol, metoprolol, nadolol, propranolol, and timolol? ☐ Yes ☐ No

☐ **YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the following question:

a. Has the patient had a documented decrease in migraine days from baseline **OR** an improvement in daily activities due to the reduction of debilitating migraines? ☐ Yes ☐ No